Side-by-side comparison of AI visibility scores, market position, and capabilities
Tend is a tech-enabled dental services organization (DSO) with 30+ US locations; raised $270M total including a $125M Series D led by Oak HC/FT in early 2025; offers dentists up to 40% commission plus equity; 579 employees as of March 2026.
Tend is a modern dental care company founded in 2018 by Andy Grover, Michael Stenclik, and Doug Hudson, and headquartered in Nashville, Tennessee. The company operates a chain of dental clinics designed to deliver a patient-centered experience that addresses two longstanding problems in dentistry: patient anxiety and dentist burnout. On the patient side, Tend's studios feature spa-like environments, consistent staffing, transparent pricing, and digital tools for scheduling, treatment planning, and care coordination — all aimed at reducing the avoidance behaviors that lead to poor oral health outcomes in adults. On the provider side, Tend offers dentists a differentiated compensation model, including commissions of up to 40% and equity participation in the company.
Consumer telehealth platform with Q3 2025 revenue of $599M (+49% YoY); 2.47M subscribers; 2025 guidance $2.3-2.4B; acquiring ZAVA for European expansion; GLP-1 weight loss, hair, and sexual health treatments shipped directly to subscribers.
Hims & Hers is a consumer telehealth and pharmacy platform founded in 2017 in San Francisco by Andrew Dudum, built on the mission of making high-quality healthcare affordable and stigma-free for conditions that people historically avoided treating due to embarrassment, cost, or access barriers. The platform's core technology combines a direct-to-consumer digital health interface with an integrated pharmacy network, enabling patients to complete asynchronous or synchronous consultations with licensed clinicians and receive prescription treatments — including compounded medications — delivered directly to their homes.\n\nHims & Hers serves patients across sexual health, hair loss, mental health, dermatology, and weight management. The company's expansion into GLP-1 compounded weight loss medications has been a significant growth catalyst, capitalizing on surging consumer demand for semaglutide and tirzepatide alternatives during periods of branded drug shortages. With 2.47 million subscribers and a subscription-centric business model, the platform generates predictable recurring revenue from patients on ongoing treatment protocols. The company's 2025 acquisition of ZAVA expands its addressable market into European telehealth markets.\n\nHims & Hers reported Q3 revenue of $599 million, a 49% year-over-year increase, and issued full-year 2025 guidance of $2.3 to $2.4 billion — a scale that makes it one of the largest consumer telehealth companies in the world. The company's ability to compound subscriber growth with expanding treatment categories and international expansion through ZAVA provides multiple vectors for continued revenue acceleration. As healthcare consumerization intensifies and patients increasingly manage chronic conditions through digital-first platforms, Hims & Hers' brand recognition, integrated pharmacy infrastructure, and subscription model give it a durable position in consumer health.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.